FGF-1
Coronary Artery Disease
Key Facts
About Zhittya Genesis Medicine
Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.
View full company profileAbout Zhittya Genesis Medicine
Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.
View full company profileAbout Zhittya Genesis Medicine
Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.
View full company profileAbout Zhittya Genesis Medicine
Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.
View full company profileAbout Zhittya Genesis Medicine
Zhittya Genesis Medicine is a clinical-stage biotech developing FGF-1, a therapeutic protein intended to induce angiogenesis (new blood vessel growth) and neurogenesis. The company's strategy targets over 75 diseases linked to poor perfusion, with active programs in neurodegenerative and cardiovascular conditions. With over 20 years and $150M in development history behind its platform, Zhittya is advancing through mid-stage trials and operates with a lean structure, leveraging partnerships for commercialization and patient logistics. Its approach offers a potentially disease-modifying treatment for chronic, underserved conditions.
View full company profileTherapeutic Areas
Other Coronary Artery Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| MUTI™ Drug‑Eluting Stent | Meril | Commercial |
| Coronary Artery Bypass Grafts | Vascudyne | Pre-clinical |
| Premier DES | Relisys Medical Devices | Commercial |
| Release R DES | Relisys Medical Devices | Commercial |
| Pristine DES | Relisys Medical Devices | Commercial |
| BioMatrix family (Flex/Alpha) | Biosensors International | Commercial |
| Coronary Artery Disease Program | Elixir Medical | Pre-clinical |
| Essential pro Stent | iVascularU | Post-Market |
| OMT-28 | OMEICOS Therapeutics | Phase 2 |
| Fantom Encore | REVA Medical | Commercial |
| Next-Gen Drug-Eluting Stents | Translumina | Development |
| Geographic Market Expansion | Translumina | Commercial |